Get the Stockscreener App
0.6199
0.48%
-0.003
Vyne Therapeutics Inc stock is traded at $0.6199, with a volume of 59,642.
It is down -0.48% in the last 24 hours and up +4.84% over the past month.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$0.6229
Open:
$0.62
24h Volume:
59,642
Relative Volume:
0.20
Market Cap:
$20.66M
Revenue:
$570.00K
Net Income/Loss:
$-26.74M
P/E Ratio:
-0.9512
EPS:
-0.6517
Net Cash Flow:
$-33.12M
1W Performance:
+1.62%
1M Performance:
+4.84%
6M Performance:
+63.73%
1Y Performance:
-65.94%
1-Day Range:
$0.60
$0.629
1-Week Range:
$0.60
$0.6299
52-Week Range:
$0.2805
$1.9933
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Name
Vyne Therapeutics Inc
Sector
Industry
Phone
800-775-7936
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Compare VYNE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
0.6199 | 20.76M | 570.00K | -26.74M | -33.12M | -0.6517 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-25 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-18-24 | Initiated | BTIG Research | Buy |
| Dec-06-21 | Resumed | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Stock (VYNE) Latest News
Death Cross: Is VYNE Therapeutics Inc a play on infrastructure spending2026 Movers & Weekly Momentum Stock Picks - baoquankhu1.vn
Market Pulse: Can VYNE Therapeutics Inc expand its profit margins2026 Retail & Weekly High Return Forecasts - baoquankhu1.vn
Breakout Watch: Can VYNE Therapeutics Inc deliver consistent dividends2026 Big Picture & Real-Time Market Sentiment Reports - baoquankhu1.vn
Layoff Watch: Can VYNE Therapeutics Inc sustain earnings growthMarket Performance Report & Momentum Based Trading Signals - baoquankhu1.vn
VYNE Stock Price, Quote & Chart | VYNE THERAPEUTICS INC (NASDAQ:VYNE) - ChartMill
Weekly Earnings: Is VYNE Therapeutics Inc stock showing strong momentumWeekly Loss Report & Community Trade Idea Sharing Platform - baoquankhu1.vn
Aug PostEarnings: What analysts say about VYNE Therapeutics Inc stockEarnings Overview Report & Real-Time Market Trend Scan - baoquankhu1.vn
Published on: 2026-04-08 14:06:22 - baoquankhu1.vn
Rate Cut: What are analysts price targets for VYNE Therapeutics Inc2026 Big Picture & Verified Trade Idea Suggestions - baoquankhu1.vn
VYNE (VYNE) CFO has 4,007 shares withheld to cover RSU taxes - Stock Titan
VYNE Therapeutics (VYNE) CSO covers taxes with 2,876 shares - Stock Titan
VYNE (VYNE) legal chief has 4,007 shares withheld to cover RSU taxes - Stock Titan
VYNE (NASDAQ: VYNE) CEO stock withheld to cover RSU tax bill - Stock Titan
Short Squeeze: Can VYNE Therapeutics Inc expand its profit marginsEarnings Risk Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE, MASI, IBCP, and HCBN - Sahm
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger–VYNE, MASI, IBCP, and HCBN - Weekly Voice
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE, MASI, IBCP, and HCBN - Benzinga
VYNE Therapeutics Stock: Merger with Yarrow Bioscience Reshapes Biotech Pipeline and Investor Landsc - AD HOC NEWS
Merger: VYNE (NASDAQ: VYNE) to combine with Yarrow; $100M financing pledged - stocktitan.net
Hedge Fund Bets: What is the long term forecast for VYNE Therapeutics Inc stockProfit Target & Real-Time Buy Signal Notifications - baoquankhu1.vn
Aug Mood: Can VYNE Therapeutics Inc expand its profit marginsPortfolio Risk Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Published on: 2026-03-27 08:05:47 - baoquankhu1.vn
ETF Watch: Does VYNE Therapeutics Inc stock have upside surprise potential2026 Catalysts & Low Drawdown Momentum Ideas - baoquankhu1.vn
If You Invested $1,000 in Vyne Therapeutics Inc (VYNE) - Stock Titan
Setup Watch: What is the long term forecast for VYNE Therapeutics Inc stockEarnings Miss & Technical Confirmation Trade Alerts - baoquankhu1.vn
VYNE SEC FilingsVyne Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Gains Report: Will VYNE Therapeutics Inc face regulatory challenges2026 Volume Leaders & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Aug Big Picture: What are analysts price targets for VYNE Therapeutics IncPortfolio Risk Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
VYNE Therapeutics Granted Nasdaq Extension to Regain Compliance - The Globe and Mail
VYNE Therapeutics Inc. Files Form 8-K: Notice of Delisting from NASDAQ and Company Information (March 11, 2026) - Minichart
VYNE Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq grants VYNE Therapeutics (VYNE) more time to fix sub-$1 share price - Stock Titan
Entry Recap: Can VYNE Therapeutics Inc sustain earnings growthOptions Play & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Aug Outlook: Can VYNE Therapeutics Inc expand its profit marginsQuarterly Portfolio Review & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Dividend Watch: What is the long term forecast for VYNE Therapeutics Inc stockJuly 2025 Closing Moves & Stepwise Swing Trade Plans - baoquankhu1.vn
Vyne Therapeutics Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Technical Analysis: What analysts say about VYNE Therapeutics Inc stockJuly 2025 Trends & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
VYNE Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
VYNE Should I Buy - Intellectia AI
VYNE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
VYNE: Losses narrowed in 2025 as the company pivots to a merger with Yarrow and exits key R&D programs - TradingView
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
VYNE Therapeutics (VYNE) to Release Quarterly Earnings on Thursday - Defense World
Aug Analyst Calls: Is Magnite Inc on track to beat earningsWeekly Profit Analysis & Verified Technical Signals - baoquankhu1.vn
Financial Contrast: Qualigen Therapeutics and VYNE Therapeutics - National Today
How VYNE Therapeutics Inc. stock performs in rate cut cyclesWatch List & Consistent Income Trade Recommendations - mfd.ru
Reviewing Avalo Therapeutics (NASDAQ:AVTX) and VYNE Therapeutics (NASDAQ:VYNE) - Defense World
Why is VYNE Therapeutics Inc. stock going upTrade Signal Summary & Proven Capital Preservation Methods - mfd.ru
VYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Large Decline in Short Interest - Defense World
Published on: 2026-02-14 10:12:41 - mfd.ru
VYNE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vyne Therapeutics Inc Stock (VYNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):